Medical Device Trials: Patient Recruitment Differences?
Praxis' director of marketing, Chris Layfield, offers insight into patient recruitment and developing a strategic recruitment plan when conducting medical device trials.
Medical Device Trials: Patient Recruitment Differences?
Chris Layfield, director of marketing at Brentwood, TN-based Praxis, told Applied Clinical Trials, “Like any trial, pharmaceutical or device, the process to developing a strategic recruitment plan is the same. One must fully understand the protocol and devise procedures to the extent that an accurate patient profile can be established. Without this, one cannot hope to effectively create a targeted reach program.”
Layfield explained after that is established, the appropriate primary, secondary and experiential research is done to determine how best to reach the persons identified in the profile – those that will be the most likely candidates for trial participation. Layfield offered this example; an acute situation where a new implantable device is being tested in heart attack patients. “If the decision to try the new device were to be needed within several hours or even less after a heart procedure then, information needs to be available to the treating physician and the family of the candidate at the time they present at the ER.”
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
